Back to Trials
NCT06971991NARecruiting

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

University of Wisconsin, Madison

Start Date

3/13/2025

Completion Date

12/1/2026

Summary

The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule Exclusion Criteria: * Pregnancy or breastfeeding * Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function. * Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure. * Patients with a physical or psychological condition that would impair study participation. * The patient is judged unsuitable for study participation by the Investigator for any other reason

Interventions

DEVICE

qDSA Blood Flow Measurement

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Transarterial EmbolismTransarterial ChemoembolizationRadioembolization

Locations

UW Hospital and Clinics

Madison, Wisconsin 53792

United States